Taxotere Lawsuit | Side Effects: Hair Loss

‏Taxotere Hair Loss Lawsuit| Taxotere Lawsuit | Side Effects: Hair Loss

‏Taxotere Hair Loss Lawsuit, Taxotere Side Effects Lawsuit, Taxotere Alopecia Lawsuit | Taxotere Lawsuit | Taxotere Chemotherapy Drug

taxotere lawsuit taxotere hair-loss-lawsuit side effects hair lossTaxotere Hair Loss Lawsuit Info: ‏Taxotere is used as a chemotherapy treatment for women with breast cancer. While temporary hair loss is expected during chemotherapy, some women who are prescribed Taxotere have suffered permanent hair loss, also known as alopecia. As a result, women are filing Taxotere hair loss lawsuits against Taxotere’s developer, Sanofi-Aventis and its subsidiaries. Cancer survivors claim Sanofi-Aventis misled women and their doctors as to the drug’s safety and did not warn them about permanent hair loss and other injuries.

‏Taxotere Hair Loss Lawsuits

taxotere lawsuit taxotere hair-loss-lawsuit side effects hair lossIn October 2016, the U.S. Judicial Panel On Multidistrict Litigation issued an order centralizing 33 Taxotere lawsuits pending in 16 different courts in the Eastern District of Louisiana. The existing and future Taxotere Hair Loss Lawsuit cases are consolidated for coordinated pretrial proceedings. (Taxotere Hair Loss Lawsuit Case No. In Re: Taxotere (Docetaxel) Products Liability Litigation – MDL 2740) One Taxotere Hair Loss lawsuit added to the mutlidistrict proceedings was filed on behalf of a Kentucky woman who allegedly suffered permanent alopecia after undergoing four cycles of chemotherapy in 2008 that included Taxotere. The Taxotere Hair Loss Lawsuit complaint asserts that Sanofi-Aventis failed to disclose Taxotere’s alopecia side effects and as a result, the plaintiff will continue to suffer from disfiguring permanent hair loss.
(Case No. 2:17-cv-00912, U.S. District Court, District of Eastern District of Louisiana)

Taxotere Studies and the efficacy of Taxotere and Taxol

‏A study published in the New England Journal of Medicine in April 2008 compared the efficacy of Taxotere and Taxol in treating breast cancer. The study found that weekly use of Taxol with certain drugs used to treat various cancers were more effective than Taxotere in improving disease-free and overall survival in women with breast cancer. Also in 2008, Sanofi-Aventis issued a press release regarding a clinical study called GEICAM 9805 which showed that Texotere improves Disease Free Survival in women with high risk node-negative breast cancer. Texotere hair loss lawsuits, however, claim the company did not include information from the study that showed alopecia persisted in 10 years and 5 months of follow-up time and was observed to be ongoing in 9.2 percent of the patients taking Taxotere.
[ ]

‏In addition to alopecia, other long-term Taxotere side effects include:

  • Excessive tearing (related to conjunctivitis or tear duct blockage)
  • Fatigue
  • Fluid retention
  • Fever
  • Gastrointestinal complications
  • Low blood cell count
  • Muscle pain
  • Sensory and motor peripheral neuropathy (numbness and tingling of the hands and feet, with loss of reflexes)
  • Skin and nail toxicity

‏Women who experience permanent alopecia allege in their Taxotere lawsuit complaints that the chemotherapy drug also caused them to suffer:

  • Economic damages
  • Inability to work because of psychological damage
  • Mental anguish
  • Severe and debilitating emotional distress
  • Loss and impairment of the quality and enjoyment of life


Taxotere Chemotherapy Drug approved by the U.S. Food and Drug Administration (FDA)

‏Taxotere (docetaxel) was approved by the U.S. Food and Drug Administration (FDA) in May 1996 to treat patients with locally advanced or metastatic breast cancer after previous chemotherapy treatments had failed. Taxotere is part of a family of drugs known as Taxanes which block cell growth by interfering with cell division. Taxotere attacks cancer cells by making the structure in some cancer cells very stiff so the cells can no longer grow.[]

warning letter from FDA about Taxotere misleading claims

‏In November 2003, the FDA sent a warning letter to Aventis Pharmaceuticals North America, the U.S. pharmaceutical business of Sanofi-Aventis, regarding three print advertisements for Taxotere. The agency found the advertisements false or misleading because they made unsubstantiated effectiveness claims, and omitted important risk information for Taxotere. The FDA issued another letter in April 2009 over promotional materials which “misleadingly” suggested Taxotere was superior to Taxol (paclitaxel), a competing Taxane drug manufactured by Bristol-Myers Squibb and used to treat breast cancer. “The FDA is unaware of substantial evidence to support these claims,” the letter said.

‏About Southern Med Law And Filing A Taxotere Hair Loss Lawsuit

‏Led by Dr. François Blaudeau, an attorney and a practicing obstetrician/ gynecologist, the legal staff at Southern Med Law possesses a deep understanding of the complex medical and legal questions at issue in Taxotere Hair Loss Lawsuits. They are not afraid to take on the nation’s largest corporations in their pursuit of justice, and are committed to ensuring that all victims have access to the type of aggressive legal advocacy that assures success. To speak to one of the firm’s Taxotere Hair Loss lawsuit attorneys for a FREE ‏Taxotere Hair Loss Lawsuit consultation please call 205-547-5525 or fill out the online form.